Promentis Pharmaceuticals, Inc. is a privately-held biopharmaceutical company based in Milwaukee, WI, dedicated to developing innovative therapies for neuropsychiatric disorders. With a focus on trichotillomania, a prevalent disorder lacking approved treatment options, the company aims to address the underlying pathology of this condition and other related obsessive-compulsive and addictive disorders through novel oral compounds that engage System xc-, a central nervous system target.
Driven by a world-class leadership team and a growing roster of recognized leaders in the biopharmaceutical industry and clinical experts in CNS disorders, Promentis Pharmaceuticals is committed to redefining what is possible in the treatment of neuropsychiatric disorders, offering hope and potential breakthroughs for patients worldwide.
Generated from the website